Immunological Approaches in the Treatment of Diabetic Nephropathy.
Cell Therapy
Chemokine
Diabetic Nephropathies
Immunomodulation
Janus Kinase Inhibitors
Phosphodiesterase Inhibitors
Vaccination
Journal
Current diabetes reviews
ISSN: 1875-6417
Titre abrégé: Curr Diabetes Rev
Pays: United Arab Emirates
ID NLM: 101253260
Informations de publication
Date de publication:
06 11 2023
06 11 2023
Historique:
received:
18
06
2023
revised:
23
08
2023
accepted:
31
08
2023
medline:
8
11
2023
pubmed:
8
11
2023
entrez:
8
11
2023
Statut:
aheadofprint
Résumé
Diabetic nephropathy (DN), the leading cause of end-stage renal disease, has no definite
treatment so far. In fact, a combination of metabolic, hemodynamic, and immunological factors
are involved in the pathogenesis of DN; therefore, effective disease management requires a
holistic approach to all predisposing contributors. Due to the recent findings about the role of inflammation
in the initiation and progression of kidney injury in diabetic patients and considerable
advances in immunotherapy methods, it might be useful to revise and reconsider the current
knowledge of the potential of immunomodulation in preventing and attenuating DN. In this review,
we have summarized the findings of add-on therapeutic methods that have concentrated on
regulating inflammatory responses in diabetic nephropathy, including phosphodiesterase inhibitors,
nuclear factor-kB inhibitors, Janus kinase inhibitors, chemokine inhibitors, anti-cytokine antibodies,
cell therapy, and vaccination.
Identifiants
pubmed: 37936470
pii: CDR-EPUB-135908
doi: 10.2174/0115733998267893231016062205
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.